ARCHITECT HBsAg Qualitative Assay, List Number 4P53 and ARCHITECT HBsAg Qualitative Confirmatory Assay, List Number 4P54 The ARCHITECT HBsAg Qualitative assay is a chemiluminescent microparticle immunoassay (CMIA) for the qualitative detection of hepatitis B surface antigen (HBsAg) in human adult and pediatric serum and plasma and neonate serum.
Publicado el 3 de abril de 2013 · Inicio del retiro: 18 de diciembre de 2012
Resumen
FDA registra el retiro Z-0987-2013 de dispositivos médicos de Clase II, publicado el 3 de abril de 2013 e iniciado el 18 de diciembre de 2012. Empresa responsable: Abbott Laboratories, Inc; Estado: Finalizado; Cantidad reportada: 12; Lote: All shipped out to this date. La Clase II indica posibles consecuencias temporales o médicamente reversibles, o una probabilidad remota de consecuencias graves.
Estado reportado al momento de publicación: Terminated — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.
Qué peligro representa
Abbott has identified that assay files for the ARCHITECT HBsAg Qualitative and HBsAg Qualitative Confirmatory assays (LNs 4P53 and 4P54) on the ARCHITECT i1000SR System were mistakenly made available on abbottdiagnostics.com in October 2012. Additionally, some i1000SR customers received notification through AbbottLink in November 2012 that assay files for LNs 4P53 and 4P54 were available. The AR
Qué hacer
Voluntary: Firm initiated · Letter
Recibe un correo cuando FDA publique un retiro como este
Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.
Detalles del retiro
- Fabricante
- Abbott Laboratories, Inc
- Distribuidor
- Nationwide Distribution including AZ, CA, FL, GA, HI, LA, MA, MD, MO, NJ, NY, PA, RI, TN, TX, UT, and WA.
- Lote
- All shipped out to this date
- Clasificación de riesgo
- Class II
- Área (FDA)
- device
- País
- United States
Retiros relacionados
- FDAAlinity s System REF 06P16-01. An automated immunoassay analyzer for In Vitro diagnostic use in blood donor18 de agosto de 2021
- FDAARCHITECT C System Mixer - Product Usage: The ARCHITECT Clinical Chemistry System is designed to perform15 de abril de 2020
- FDAC4 is an in vitro diagnostic assay for the quantitative determination of C4 in human serum or plasma. Antigen31 de julio de 2019
- FDAARCHITECT c4000 part number 02P24; ARCHITECT c8000 part number 01G06; ARCHITECT c16000 part number 03L7729 de noviembre de 2017
- FDANeedle Counters with Blade Disarmer; 12.2 x 10.5 x 3.5 cm; 60 Count/100 Capacity; Sterile; Removable Numbered3 de abril de 2013
- FDASiemens Dimension Vista(R) Alkaline Phosphatase (ALP) Calibrator The ALP CAL is an in vitro diagnostic product3 de abril de 2013
Preguntas sobre este retiro
¿ARCHITECT HBsAg Qualitative Assay, List Number 4P53 and ARCHITECT HBsAg Qualitative Confirmatory Assay, List Number 4P54 The ARCHITECT HBsAg Qualitative assay is a chemiluminescent microparticle immunoassay (CMIA) for the qualitative detection of hepatitis B surface antigen (HBsAg) in human adult and pediatric serum and plasma and neonate serum. fue retirado del mercado?
Sí. FDA publicó el retiro Z-0987-2013 el 3 de abril de 2013. Peligro reportado: Abbott has identified that assay files for the ARCHITECT HBsAg Qualitative and HBsAg Qualitative Confirmatory assays (LNs 4P53 and 4P54) on the ARCHITECT i1000SR System were mistakenly made available on abbottdiagnostics.com in October 2012. Additionally, some i1000SR customers received notification through AbbottLink in November 2012 that assay files for LNs 4P53 and 4P54 were available. The AR
¿Qué debo hacer si tengo este producto?
Voluntary: Firm initiated · Letter